YP1B Stock Overview
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Immutep Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.23 |
| 52 Week High | AU$0.31 |
| 52 Week Low | AU$0.13 |
| Beta | 1.83 |
| 1 Month Change | 8.49% |
| 3 Month Change | 20.42% |
| 1 Year Change | 59.72% |
| 3 Year Change | -14.34% |
| 5 Year Change | 76.92% |
| Change since IPO | -50.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| YP1B | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 16.2% | -0.2% | 0.5% |
| 1Y | 59.7% | -22.8% | 1.3% |
Return vs Industry: YP1B exceeded the German Biotechs industry which returned -23% over the past year.
Return vs Market: YP1B exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| YP1B volatility | |
|---|---|
| YP1B Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: YP1B has not had significant price volatility in the past 3 months.
Volatility Over Time: YP1B's weekly volatility has decreased from 23% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Marc Voigt | www.immutep.com |
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease.
Immutep Limited Fundamentals Summary
| YP1B fundamental statistics | |
|---|---|
| Market cap | €324.97m |
| Earnings (TTM) | -€24.60m |
| Revenue (TTM) | €2.39m |
136.1x
P/S Ratio-13.2x
P/E RatioIs YP1B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YP1B income statement (TTM) | |
|---|---|
| Revenue | AU$3.93m |
| Cost of Revenue | AU$37.72m |
| Gross Profit | -AU$33.79m |
| Other Expenses | AU$6.71m |
| Earnings | -AU$40.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.034 |
| Gross Margin | -859.57% |
| Net Profit Margin | -1,030.32% |
| Debt/Equity Ratio | 0.8% |
How did YP1B perform over the long term?
See historical performance and comparison